Entity

Time filter

Source Type

Boadilla del Monte, Spain

Truta Z.,Babes - Bolyai University | Truta M.,Cluj Clinic Hospital | Micu R.,IVF Laboratory
Romanian Biotechnological Letters | Year: 2012

Free energy released from the hydrolysis of adenosine triphosphate is required for spermatozoa movement, and the spermatozoa velocity is influenced by magnetic field. Since glucose is necessary for maintenance of optimal adenosine triphosphate levels, a question arises: is the human spermatozoa glucose consumption influenced by zero magnetic field conditions? The effect of zero magnetic field on human semen glucose consumption was investigated in connection with the main natural fertilization parameters: viability and motility of spermatozoa cells. We report, for the first time, that human spermatozoa glucose consumption is accelerated in vitro in zero magnetic field conditions. © 2012 University of Bucharest. Source


Silva J.,University of Beira Interior | Fazendeiro P.,University of Beira Interior | Mondejar F.J.P.,IVF Laboratory | Pinto S.,Maternidade Doutor Alfredo da Costa
Advances in Intelligent Systems and Computing | Year: 2014

This paper proposes an assessment model of putative embryos for in vitro fertilization (IVF) based on a triangular norm. One of the most common difficulties of IVF treatments is multiple pregnancy. Therefore the number of embryos for transfer is of paramount importance considering the need to reduce the incidence of multiple births without compromising overall pregnancy rates in fertility treatments. Consequently the selective embryo transfer is recommended to optimize efficacy and safety outcomes. The embryo evaluation is of enormous relevance, since it directly affects the success of different techniques used in assisted reproductive technologies (ART). The gathering of all the information needed to embryo evaluation, as well as software that can serve as aid in the decision is of great importance. The tool herein presented accomplishes these two objectives. The analysis of the requirements of the assessment process has resulted in a flexible data model, used in the presented prototype, supporting the selective embryo transfer decision-making process. © Springer International Publishing Switzerland 2014. Source


Korthorst R.A.,St Elisabeth Hospital | Consten D.,IVF Laboratory | Van Roijen J.H.,St Elisabeth Hospital
BJU International | Year: 2010

Study Type - Diagnostic (non-consecutive) Level of Evidence 3b Objective To evaluate the safety and efficacy of a new semen analysis protocol after vasectomy, where clearance is given to patients who provide a single semen sample with <100 000 immotile sperm/mL at ≥3 months after vasectomy. Patients and Methods Between 1 July 2005 and 31 March 2008, 1073 men provided a first semen sample at ≥3 months after vasectomy. Semen was first evaluated on a wet-slide preparation. Those samples with no ('azoospermia') or sporadic immotile spermatozoa could be cleared without further analysis. Samples with motile sperm were immediately labelled as potentially fertile, while those with a significant number of immotile sperm were re-analysed using a Neubauer haemocytometer. All samples with <100 000 immotile sperm/mL were cleared. Results Of men providing semen at 3 months after vasectomy, 96% could be cleared. No sperm were seen ('azoospermia') in 51.3% of samples, and 44.7% of samples contained <100 000 immotile sperm. No paternity has been reported in the cleared group after a follow-up of at least 1 year. Conclusions A protocol stipulating that patients can be cleared after a single semen sample containing <100 000 immotile sperm/mL at ≥3 months after vasectomy is safe and dramatically reduces the number of men who cannot be cleared at 3 months after vasectomy. © 2009 BJU INTERNATIONAL. Source


Pasquier C.,Toulouse University Hospital Center | Andreutti C.,Laboratory Of Clinique Of La Source | Bertrand E.,IVF Laboratory | Bostan A.,Human Reproduction Research Laboratory | And 13 more authors.
Journal of Medical Virology | Year: 2012

Detection of HIV-1 RNA in semen is used commonly to determine the safety of semen processing procedures before assisted reproductive technology (ART). Using two panels of prepared semen samples containing HIV-1 the performances of protocols from 14 centers have been compared. No false-positive results were detected but false-negative results were frequent when the concentration was below 500 HIV-1 RNA copies/ml of seminal plasma. Frequency of HIV-1 RNA detection was higher on seminal cells than on seminal plasma. Assays (or protocols) for quantifying HIV-1 RNA in semen performed less well than standardized blood plasma assays. The HIV load in seminal plasma could be a useful marker of the risk of sexual transmission of the virus. Its use as a marker of global HAART efficiency in the HIV reservoir needs further study. Standardized assays are required for detection and measurement of HIV-1 RNA in semen samples. © 2011 Wiley Periodicals, Inc. Source


De Los Santos M.J.,IVF Laboratory | Ruiz A.,IVI Valencia
Fertility and Sterility | Year: 2013

In view of the increasing emphasis being placed on patient safety and quality health care, it is extremely important to develop fail-safe mechanisms to prevent assisted reproductive technology (ART) mix-ups. Sample mismatch is the most undesirable event that can occur in an IVF laboratory as it may have catastrophic consequences for both patients and health care professionals. Many strategies can be adopted to reduce laboratory errors, such as improved quality control and quality assessment, certification, educational programs, and external quality assessment. Nevertheless, none suffices to absolutely prevent this error. Therefore, the implementation of specific policies, such as double-checking safety protocols, is receiving more and more interest. After some adverse events involving sample misidentification occurred in some countries, double-checking every step of the IVF clinical and laboratory procedure has become mandatory. However, double-checking protocols can also prove difficult to implement and a new generation of errors may occur. Other approaches, including electronic strategies for tracking, and even microlabeling embryos, are currently being evaluated. © 2013 American Society for Reproductive Medicine, Published by Elsevier Inc. Source

Discover hidden collaborations